The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial

PURPOSE: The AVAglio trial reported a significant survival benefit for first line bevacizumab treatment in patients with IDH wildtype glioblastoma of the proneural gene expression subtype. We here aim to replicate these findings in an independent trial cohort. METHODS: We evaluate the treatment bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Weller, Johannes, Zeyen, Thomas, Schäfer, Niklas, Schaub, Christina, Potthoff, Anna-Laura, Steinbach, Joachim P., Hau, Peter, Seidel, Clemens, Goldbrunner, Roland, Tabatabai, Ghazaleh, Vatter, Hartmut, Tzaridis, Theophilos, Schneider, Matthias, Herrlinger, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Case Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589156/
https://www.ncbi.nlm.nih.gov/pubmed/37787906
http://dx.doi.org/10.1007/s11060-023-04470-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589156/
https://www.ncbi.nlm.nih.gov/pubmed/37787906
http://dx.doi.org/10.1007/s11060-023-04470-9

Ejemplares similares